A comprehensive review of the anticancer effects of decursin
Open Access
- 20 February 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1303412
Abstract
Cancer is a globally complex disease with a plethora of genetic, physiological, metabolic, and environmental variations. With the increasing resistance to current anticancer drugs, efforts have been made to develop effective cancer treatments. Currently, natural products are considered promising cancer therapeutic agents due to their potent anticancer activity and low intrinsic toxicity. Decursin, a coumarin analog mainly derived from the roots of the medicinal plant Angelica sinensis, has a wide range of biological activities, including anti-inflammatory, antioxidant, neuroprotective, and especially anticancer activities. Existing studies indicate that decursin affects cell proliferation, apoptosis, autophagy, angiogenesis, and metastasis. It also indirectly affects the immune microenvironment and can act as a potential anticancer agent. Decursin can exert synergistic antitumor effects when used in combination with a number of common clinical anticancer drugs, enhancing chemotherapy sensitivity and reversing drug resistance in cancer cells, suggesting that decursin is a good drug combination. Second, decursin is also a promising lead compound, and compounds modifying its structure and formulation form also have good anticancer effects. In addition, decursin is not only a key ingredient in several natural herbs and dietary supplements but is also available through a biosynthetic pathway, with anticancer properties and a high degree of safety in cells, animals, and humans. Thus, it is evident that decursin is a promising natural compound, and its great potential for cancer prevention and treatment needs to be studied and explored in greater depth to support its move from the laboratory to the clinic.Keywords
This publication has 132 references indexed in Scilit:
- Decursin inhibits EGFR‐ERK1/2 signaling axis in advanced human prostate carcinoma cellsThe Prostate, 2023
- Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancersJournal of Cellular Physiology, 2019
- JH‐4 reduces HMGB1‐mediated septic responses and improves survival rate in septic miceJournal of Cellular Biochemistry, 2018
- Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signaling pathwayPhytotherapy Research, 2018
- Recent Advances in the Chemistry and Biology of PodophyllotoxinsChemistry – A European Journal, 2017
- Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR‐RES Ovarian Cancer Cells via Inhibition of P‐glycoprotein ExpressionPhytotherapy Research, 2016
- Anticancer effects of cantharidin in A431 human skin cancer (Epidermoid carcinoma) cells in vitro and in vivoEnvironmental Toxicology, 2016
- Decursin Exerts Anti‐cancer Activity in MDA‐MB‐231 Breast Cancer Cells Via Inhibition of the Pin1 Activity and Enhancement of the Pin1/p53 AssociationPhytotherapy Research, 2013
- Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and functionJournal of Cellular Biochemistry, 2012
- Decursin and Decursinol from Angelica gigas Inhibit the Lung Metastasis of Murine Colon CarcinomaPhytotherapy Research, 2010